Synonym
Triletide; Triletidum; Triletida;
IUPAC/Chemical Name
methyl acetyl-L-phenylalanyl-L-phenylalanyl-L-histidinate
InChi Key
ZHAGGRWTJXROKV-HJOGWXRNSA-N
InChi Code
InChI=1S/C27H31N5O5/c1-18(33)30-22(13-19-9-5-3-6-10-19)25(34)31-23(14-20-11-7-4-8-12-20)26(35)32-24(27(36)37-2)15-21-16-28-17-29-21/h3-12,16-17,22-24H,13-15H2,1-2H3,(H,28,29)(H,30,33)(H,31,34)(H,32,35)/t22-,23-,24-/m0/s1
SMILES Code
O=C(OC)[C@H](CC1=CNC=N1)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=CC=C3)NC(C)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
505.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Repossini L. Preliminary human pharmacokinetics of triletide. Pharmatherapeutica. 1985;4(3 Spec No):189-94. PubMed PMID: 4059299.
2: d'Ambrosio G, d'Annabile A. Effects of combined treatment with triletide and cimetidine in gastric and duodenal ulcer patients, and a retrospective comparison with cimetidine alone. Pharmatherapeutica. 1985;4(3 Spec No):171-6. PubMed PMID: 4059298.
3: Trabucchi E, Longoni F, Baratti C, Boccasanta P. Clinical evaluation of triletide versus antacids in the treatment of duodenal ulcer out-patients. Pharmatherapeutica. 1985;4(3 Spec No):161-5. PubMed PMID: 4059297.
4: Waucquez JL. Dose-finding clinical assay of triletide in gastric and duodenal ulceration. Pharmatherapeutica. 1985;4(3 Spec No):146-54. PubMed PMID: 4059296.
5: Maggi CA, Ferrari D. Cytoprotective approach to peptic ulcer therapy: a preliminary dose-finding clinical investigation with triletide. Pharmatherapeutica. 1985;4(3 Spec No):141-5. PubMed PMID: 4059295.
6: Gandolfi L, Solmi L. Triletide and ranitidine for the management of chronic duodenal ulcer: a controlled clinical investigation. Pharmatherapeutica. 1985;4(3 Spec No):182-8. PubMed PMID: 3903787.
7: Primbs P. Triletide in a cimetidine-controlled clinical evaluation in duodenal ulcer patients. Pharmatherapeutica. 1985;4(3 Spec No):177-81. PubMed PMID: 3903786.
8: Campisi D, Cataldo MG, Paterna S, Bivona A, Barbarino C. Cytoprotective therapy of gastric ulcers: a controlled clinical evaluation of triletide versus carbenoxolone. Pharmatherapeutica. 1985;4(3 Spec No):166-70. PubMed PMID: 3903785.
9: Hoetzinger H. Controlled clinical assessment of the efficacy and tolerance of triletide versus antacids in patients with gastric and duodenal ulcers. Pharmatherapeutica. 1985;4(3 Spec No):155-60. PubMed PMID: 3903784.
10: Moroni D, Gervasi GB, Patella P, Visentin L, Maselli MA, Bergamaschi M. The tripeptide ZAMI-420 inhibits thromboxane-induced gastric vasoconstriction and ischaemia. Int J Tissue React. 1983;5(3):249-52. PubMed PMID: 6654624.
11: Gervasi GB, Fossati A, Caliari S, Rapalli L, Bergamaschi M. Prevention of experimentally induced gastric damage with the tripeptide ZAMI-420, a new thromboxane synthesis inhibitor. Int J Tissue React. 1983;5(3):253-6. PubMed PMID: 6418678.
